Goldman Sachs analyst Rajan Sharma initiated coverage of UCB (UCBJF) with a Buy rating and EUR 250 price target The firm views UCB as a “rare opportunity” within European biopharma, offering a “significant blockbuster” launch through Bimzelx at a compelling entry point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF: